Is AngioDynamics, Inc. overvalued or undervalued?

As of 5 January 2024, AngioDynamics, Inc. has moved from an attractive to a risky valuation grade. The company is currently considered overvalued. Key ratios include a Price to Book Value of 2.44, an EV to EBITDA of 410.27, and a ROCE of -18.35%.
In comparison to peers, AngioDynamics has a significantly negative P/E ratio of -21.90, while CareDx, Inc. is very attractive with a P/E of -58.59, and Organogenesis Holdings, Inc. is also risky with a P/E of 29.15. Notably, AngioDynamics has underperformed relative to the S&P 500 in the past three years, with a return of -50.42% compared to the S&P 500's 58.74%.